FDA 483 - Fresenius Kabi USA, LLC - May 14, 2026
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Fresenius Kabi USA, LLC, a sterile drug manufacturer in Grand Island, NY, was cited for significant deficiencies in its quality control systems. Observations included inadequate procedures for production and process controls, particularly concerning visual inspection of sterile vials, and insufficient validation of aseptic and sterilization processes. Additionally, the firm failed to perform comparative testing for analytical method transfers under actual conditions of use.
ID · 48b37132-1acd-44cc-84d6-ca784a5d2932